A Randomized, Double-blind, Phase IIb Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine (FQ) With Artefenomel (OZ439) in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria

Trial Profile

A Randomized, Double-blind, Phase IIb Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine (FQ) With Artefenomel (OZ439) in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jan 2018

At a glance

  • Drugs Artefenomel (Primary) ; Artefenomel/ferroquine (Primary) ; Ferroquine (Primary)
  • Indications Falciparum malaria
  • Focus Therapeutic Use
  • Acronyms FALCI
  • Sponsors Sanofi
  • Most Recent Events

    • 10 Jan 2018 Planned End Date changed from 2 Jul 2019 to 23 Jul 2019.
    • 10 Jan 2018 Planned primary completion date changed from 2 Jul 2019 to 23 Jul 2019.
    • 18 Dec 2017 Planned End Date changed from 1 Feb 2019 to 2 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top